Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
about
Novel strategies to target the ubiquitin proteasome system in multiple myelomaInterpretation of cytogenetic results in multiple myeloma for clinical practiceNew investigational drugs with single-agent activity in multiple myelomaTowards Stratified Medicine in Plasma Cell MyelomaOutcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Waldenstrom macroglobulinemia: prognosis and management.Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patientsMicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myelomaRelationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies.A voluminous mass as an initial clinical symptom of multiple myeloma: A case reportMyeloma today: Disease definitions and treatment advances.Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations.Hematolymphoid Lesions of the Sinonasal Tract.Successful treatment of a primary gastric plasmacytoma mimicking intractable gastric ulcer by using high-dose dexamethasone therapy: a case reportA retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: a single center study in Korea.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response.Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis.Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.Mandibular destructive radiolucent lesion: The first sign of multiple myeloma.Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma.Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.An Overview of Bortezomib-Induced NeurotoxicityHeparanase: From basic research to therapeutic applications in cancer and inflammation.Economic burden of multiple myeloma among patients in successive lines of therapy in the United States.Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion.Advances in the Treatment of Paraproteinemic Neuropathy.The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma.Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project.
P2860
Q26773246-C8B520CF-0073-4155-AF81-1A8CED407D79Q26777803-80E47E3A-6411-4BA9-AED3-FA40FAC0759FQ28071551-E730D2EA-AB8E-4C1E-BDAC-7B36C24BE298Q28074994-0192B2DA-F7E8-4CD6-B215-8BCB1CBCC9BDQ30276010-2BC47004-2998-4370-B6F6-E0155A968BA6Q30313340-E306C4DD-4DB0-4EE4-B661-D955030F5404Q31154933-D969270F-689B-4B92-A6B2-9E5D0DF9D2C7Q33600826-011419A3-5802-4E88-9C91-52112B7248A4Q33721123-D14D8897-593F-4E35-8A1E-968ECE10D56BQ35244911-DEA895CB-8C63-42FB-AD52-9DC6D912ECABQ35765157-86339C88-EA6E-4228-A81E-E0815297A48CQ35766816-930928C6-1630-4CB0-A518-BE2E296BC800Q35789280-DFBB6346-457D-4DAD-B947-69C0B4E69DB8Q35830856-130A3186-DCF1-4455-96DD-ECC5223565A0Q36335530-A35002A3-278A-4A8D-B9D0-2B431E57AF62Q36470699-8C3ABEE5-A601-4B5B-90BF-946DDCCAB70AQ36494358-46B47F48-828F-42E0-85D1-3C4BB88F6FDBQ36558579-8DE56BBC-3781-4560-A762-A25DFF093E0DQ36758335-DF33967F-844E-4AED-9A94-D526376C4FBEQ37062707-60B6842E-4271-4524-8819-7EB7CD41AA59Q37623809-F2A9FE30-B0DA-42D5-9214-D3D4A82AB433Q38662337-315345BA-DD54-478C-9D37-F2244092A93FQ38697483-34FBC5D6-1A83-4EEC-A115-FB1C3D63E942Q38815363-9ACB812C-356F-418F-96D8-49604EF3F63BQ38929051-2E49B6C8-454D-4555-88BB-FF5C5F702DFAQ39024142-2DACF755-0188-46C3-A3FB-032ED6BDDA3CQ39923951-798FE26A-D7F8-45C9-961C-8FDD717FDB7BQ40469944-56FF9463-12CD-434A-A802-886289B15780Q41198089-C7F42012-E5BB-4620-ABDF-B6F8CA299883Q41263157-38104496-2243-4144-84EE-1B1DA496339CQ41609674-EA50E466-3735-4EAA-B6AD-0F968E030A75Q41701970-01D86A4A-F88D-4D38-9FE0-AAFA46109FCCQ41708947-77771E82-2C43-46A9-B521-566AFA18F9C2Q42361419-23591287-6412-4F6A-96A7-D3F5DC20DC89Q42587945-030E044E-B9B3-4D37-802F-816D3F2F58CBQ44561473-1C8032C4-F39A-4BA5-8E8C-B4AEDB859D46Q47707509-3D62A433-424D-487D-96FA-9C520271A9DDQ47790104-94017833-A8AE-4FE4-BE54-57970E4335A3Q48153195-509134C6-C1B4-4989-A3B9-319385A8679AQ50145894-508AFB51-88FC-43D7-9276-059D80203849
P2860
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@ast
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@en
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@nl
type
label
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@ast
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@en
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@nl
prefLabel
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@ast
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@en
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@nl
P2860
P3181
P356
P1476
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
@en
P2093
S. Vincent Rajkumar
P2860
P304
P3181
P356
10.1002/AJH.23810
P407
P577
2014-10-01T00:00:00Z